AbbVie Inc (ABBV)vsSoleno Therapeutics Inc (SLNO)
ABBV
AbbVie Inc
$246.12
+0.98%
HEALTHCARE · Cap: $430.82B
SLNO
Soleno Therapeutics Inc
$53.01
0.00%
HEALTHCARE · Cap: $2.76B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 22491% more annual revenue ($64.39B vs $285.01M). SLNO leads profitability with a 33.7% profit margin vs 9.8%. SLNO trades at a lower P/E of 27.4x. ABBV earns a higher WallStSmart Score of 73/100 (B).
ABBV
Strong Buy73
out of 100
Grade: B
SLNO
Buy52
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-63.1%
Fair Value
$150.90
Current Price
$246.12
$95.22 premium
Intrinsic value data unavailable for SLNO.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 39.6%
Earnings expanding 290.4% YoY
Conservative balance sheet, low leverage
Keeps 34 of every $100 in revenue as profit
Strong operational efficiency at 33.6%
Every $100 of equity generates 26 in profit
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
Moderate valuation
0.0% revenue growth
0.0% earnings growth
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. Revenue growth of 10.2% demonstrates continued momentum. PEG of 0.41 suggests the stock is reasonably priced for its growth.
Bull Case : SLNO
The strongest argument for SLNO centers on Profit Margin, Operating Margin, Return on Equity. Profitability is solid with margins at 33.7% and operating margin at 33.6%.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 68.9x leaves little room for execution misses.
Bear Case : SLNO
The primary concerns for SLNO are P/E Ratio, Revenue Growth, EPS Growth.
Key Dynamics to Monitor
ABBV carries more volatility with a beta of 0.28 — expect wider price swings.
ABBV is growing revenue faster at 10.2% — sustainability is the question.
ABBV generates stronger free cash flow (3.6B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ABBV scores higher overall (73/100 vs 52/100) and 10.2% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Soleno Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of rare diseases. The company is headquartered in Redwood City, California.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?